Breaking Down BTK Degraders in CLL

Nirav N. Shah, MD, MSHP, and Alexey Danilov, MD, PhD, discuss the phase 2 DAYBreak CLL-201 trial evaluating bexobrutideg in relapsed/refractory CLL.

Alexey Danilov, MD, PhD, discusses DAYBreak CLL-201 and how it plans to evaluate bexobrutideg in chronic lymphocytic leukemia.

Nirav N. Shah, MD, MSHP, discusses bexobrutideg and what the BTK degrader could bring to chronic lymphocytic leukemia management.

Nirav N. Shah, MD, MSHP, discusses the design of DAYBreak CLL-201 and its potential importance for chronic lymphocytic leukemia management.